BIO
$264.49-0.51 (-0.19%)
Bio-Rad Laboratories, Inc.
Recent News
Disappointing Results Hurt Bio-Rad Laboratories (BIO)
Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf Partners Global Fund”. A copy of the letter can be downloaded here. The Fund returned 5.27% in the quarter, compared to the MSCI World’s 3.12 % and the MSCI World Value’s 3.34% return. The Fund returned 16.72% for the year, compared […]
Assessing Whether Bio-Rad Laboratories (BIO) Looks Undervalued After Recent Share Price Softness
Assessing Bio-Rad Laboratories after recent performance Bio-Rad Laboratories (BIO) has attracted attention after a mixed stretch of returns, with the stock roughly flat over the past year but showing declines over the past month and past 3 months. See our latest analysis for Bio-Rad Laboratories. At the latest share price of $271.44, Bio-Rad’s short term share price momentum has been fading, while its 1 year total shareholder return of 9.56% contrasts with much weaker 3 and 5 year total...
International Markets and Bio-Rad (BIO): A Deep Dive for Investors
Examine Bio-Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth
Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter and full-year results despite a challenging year marked by geopolitical uncertainty and continued pressure on academic research. The company delivered modest revenue growth and strong free cash […]
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down
BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.